| 1 |
35321823 | Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI. | 2022 Jul |
1 |
| 2 |
33558152 | Assessment of The High risk and unmEt Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population. | 2021 Apr |
1 |
| 3 |
33985681 | Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. | 2021 May 18 |
1 |
| 4 |
34424771 | Applying Decision Analysis to Inform the US Food and Drug Administration's Benefit-Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMIS. | 2021 Aug 24 |
1 |
| 5 |
34814698 | Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. | 2021 Dec |
1 |
| 6 |
32662726 | An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. | 2020 Aug |
1 |
| 7 |
32704557 | Assessment of the high risk and unmet need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource utilization, cost and burden of illness in the Diabetes Collaborative Registry. | 2020 Jul |
1 |
| 8 |
30788847 | Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. | 2019 May |
1 |